Effect of anaplerotic treatment on brain energy profile evolution in early stage of the Huntington disease
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2016
Price : $35 *
At a glance
- Drugs Triheptanoin (Primary)
- Indications Huntington's disease
- Focus Pharmacodynamics; Proof of concept
- Acronyms TRIHEP2
- 07 Jan 2015 According to an Ultragenyx Pharmaceutical media release, results were published in the online issue of Neurology in 2015.
- 12 Aug 2013 New trial record
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.